Vorapaxar
Back to searchMolecule Structure
Scientific Name
Vorapaxar
Description of the Drug
Vorapaxar is a platelet aggregation inhibitor used to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09030
http://www.drugbank.ca/drugs/DB09030
Brand Name(s)
Not Available
Company Owner(s)
Xspire Pharma
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Proteinase-activated receptor 1 | SINGLE PROTEIN | ANTAGONIST | CHEMBL3974 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL471187 | ||
| DrugBank | DB09030 | ||
| PubChem: Thomson Pharma | 16419431 | ||
| PubChem | 10077130 | ||
| Nikkaji | J2.419.474D | J2.933.500A | |
| PDBe | VPX | ||
| DrugCentral | 4870 | ||
| ChemicalBook | CB32628522 | ||
| Guide to Pharmacology | 4047 | ||
| rxnorm | ZONTIVITY | VORAPAXAR SULFATE | VORAPAXAR |
| PubChem: Drugs of the Future | 81044371 | ||
| ChEBI | 82702 | ||
| ZINC | ZINC000003925861 |
